United Therapeutics Corporation will present at the 41st Annual JP Morgan Healthcare Conference


Receive instant alerts when news breaks about your stocks. Request a one-week free trial at StreetInsider Premium here.


SILVER SPRINGS, Md. & RESEARCH TRIANGLE PARK, NC-(BUSINESS WIRE)– United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine Rothblattchairman and chief executive officer, will provide an overview and update on the company’s operations during a fireside chat at the 41st Annual JP Morgan Healthcare Conference in San Francisco.

The session will be held on Monday, January 9, 2023, from 1:30 PM to 2:10 PM PST and may be accessed via a live webcast on United Therapeutics’ website at https://ir.unither. com/events-and-presentations. An archived, recorded version of the session will be available approximately 24 hours after the session ends and will be accessible in the same location for 30 days.

United Therapeutics: Enabling inspiration

At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity and persistence to innovate for the unmet medical needs of our patients and for the benefit of other stakeholders. We are bold and unconventional. We have fun, we do good. We are the first public biotech or pharmaceutical company to take the form of a public benefit corporation (PBC). Our public benefit purpose is ensure a brighter future for patients through (a) the development of new pharmaceutical therapies; and (b) technologies that expand the availability of organs for transplantation.

You can learn more about what it means to be a PBC here: unither.com/PBC.

Forward-looking statements

Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among other things, our efforts to innovate for the unmet medical needs of our patients, for the benefit of our other stakeholders, and to achieve our public good purpose of developing new pharmaceutical therapies and technologies that expand the availability of organs for transplantation. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10 -Q, and current reports on Form 8-K. We claim the safe harbor protections contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of January 2, 2023 and undertake no obligation to update or revise the information contained in this press release whether as a result of new information, future events or for any other reason.

Dewey Steadman at (202) 919-4097

E-mail: [email protected]

Source: United Therapeutics Corporation

Leave a Comment

Your email address will not be published. Required fields are marked *